Renaissance Technologies's PTGX Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 8,167 shares of Protagonist Therapeutics, Inc. (PTGX) worth $713,306, representing 0.00% of the portfolio. First purchased in 2017-Q2, this long-term strategic position has been held for 31 quarters.
Based on 13F filings, Renaissance Technologies has maintained a strategic position in PTGX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2023, adding 432,000 shares. Largest reduction occurred in Q4 2020, reducing 300,903 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Protagonist Therapeutics (PTGX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Protagonist Therapeutics (PTGX) Trades by Renaissance Technologies
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +8,167 | New Buy | 8,167 | $87.34 |
| Q3 2025 | -173,134 | Sold Out | 0 | $0.00 |
| Q2 2025 | -150,433 | Reduce 46.49% | 173,134 | $55.27 |
| Q1 2025 | +102,400 | Add 46.30% | 323,567 | $48.36 |
| Q4 2024 | +77,000 | Add 53.41% | 221,167 | $38.60 |
| Q3 2024 | -153,300 | Reduce 51.54% | 144,167 | $45.00 |
| Q2 2024 | +264,900 | Add 813.40% | 297,467 | $34.65 |
| Q1 2024 | -181,400 | Reduce 84.78% | 32,567 | $28.92 |
| Q4 2023 | -12,301 | Reduce 5.44% | 213,967 | $22.93 |
| Q3 2023 | -163,999 | Reduce 42.02% | 226,268 | $16.68 |
| Q2 2023 | -300,600 | Reduce 43.51% | 390,267 | $0.03 |
| Q1 2023 | +432,000 | Add 166.88% | 690,867 | $0.02 |
| Q4 2022 | -140,900 | Reduce 35.25% | 258,867 | $0.01 |
| Q3 2022 | +76,900 | Add 23.82% | 399,767 | $8.43 |
| Q2 2022 | +303,400 | Add 1558.53% | 322,867 | $7.91 |
| Q1 2022 | +19,467 | New Buy | 19,467 | $23.68 |
| Q1 2021 | -35,797 | Sold Out | 0 | $0.00 |
| Q4 2020 | -300,903 | Reduce 89.37% | 35,797 | $20.17 |
| Q3 2020 | -195,600 | Reduce 36.75% | 336,700 | $19.55 |
| Q2 2020 | -43,100 | Reduce 7.49% | 532,300 | $17.66 |
| Q1 2020 | -42,724 | Reduce 6.91% | 575,400 | $7.06 |
| Q4 2019 | +63,024 | Add 11.35% | 618,124 | $7.05 |
| Q3 2019 | +42,800 | Add 8.35% | 555,100 | $12.01 |
| Q2 2019 | +107,300 | Add 26.49% | 512,300 | $12.11 |
| Q1 2019 | +65,200 | Add 19.19% | 405,000 | $12.57 |
| Q4 2018 | -197,400 | Reduce 36.75% | 339,800 | $6.73 |
| Q3 2018 | +58,900 | Add 12.31% | 537,200 | $10.29 |
| Q2 2018 | +426,100 | Add 816.28% | 478,300 | $6.72 |
| Q1 2018 | +52,200 | New Buy | 52,200 | $8.58 |
| Q3 2017 | -25,989 | Sold Out | 0 | $0.00 |
| Q2 2017 | +25,989 | New Buy | 25,989 | $11.31 |
Renaissance Technologies's Protagonist Therapeutics Investment FAQs
Renaissance Technologies first purchased Protagonist Therapeutics, Inc. (PTGX) in Q2 2017, acquiring 25,989 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Protagonist Therapeutics, Inc. (PTGX) for 31 quarters since Q2 2017.
Renaissance Technologies's largest addition to Protagonist Therapeutics, Inc. (PTGX) was in Q1 2023, adding 690,867 shares worth $15,890.
According to the latest 13F filing for Q4 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 8,167 shares of Protagonist Therapeutics, Inc. (PTGX), valued at approximately $713,306.
As of the Q4 2025 filing, Protagonist Therapeutics, Inc. (PTGX) represents approximately 0.00% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies's peak holding in Protagonist Therapeutics, Inc. (PTGX) was 690,867 shares, as reported at the end of Q1 2023.